Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients

Drugs of Today

Volumn 44, Issue 7, 2008, Pages 515-530

  Tamura, Kimberly ^a,b   Drew, Richard ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POSACONAZOLE; PREDNISONE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG CHOICE; DRUG MECHANISM; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; IMMUNE DEFICIENCY; LIVER TOXICITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; PATIENT SELECTION; PHOTOTOXICITY; PROPHYLAXIS; RASH; RECOMMENDED DRUG DOSE; REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES;

EID: 51349159745     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.7.1230943     Document Type: Review

References (76)

1. Pappas, P.G., Rex, J.H., Lee, J. et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37(5): 634-43.
2. Lin, S.J., Schranz, J., Teutsch, S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001, 32(3): 358-66.
3. Gudlaugsson, O., Gillespie, S., Lee, K. et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9): 1172-7.
4. Marr, K.A., Carter, R.A., Crippa, F., Wald, A., Corey, L. Epidemiology and outcome of mold infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7): 909-17.
5. Morgan, J., Meltzer, M.I., Plikaytis, B.D. et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26(6): 540-7.
6. Wilson, L.S., Reyes, C.M., Stolpman, M., Speckman, J., Allen, K., Beney, J. The direct cost and incidence of systemic fungal infections. Value Health 2002, 5(1): 26-34.
7. Zaoutis, T.E., Argon, J., Chu, J., Berlin, J.A., Walsh, T.J., Feudtner, C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005, 41(9): 1232-9.
8. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel R.P., Edmond, M.B. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3): 309-17.
9. Hajjeh, R.A., Sofair, A.N., Harrison, L.H. et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42(4): 1519-27.
10. Reingold, A.L., Lu, X.D., Plikaytis, B.D., Ajello, L. Systemic mycoses in the United States, 1980-1982. J Med Vet Mycol 1986, 24(6): 433-6.
11. Rees, J.R., Pinner, R.W., Hajjeh, R.A., Brandt, M.E., Reingold, A.L. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance. Clin Infect Dis 1998, 27(5): 1138-47.
12. Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R. F., Wenzel R.P. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988, 148(12): 2642-5.
13. Marr, K.A., Carter, R.A., Boeckh, M., Martin, P., Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002, 100(13): 4358-66.
14. Ribaud, P., Chastang, C., Latge, J.P. et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999, 28(2): 322-30.
15. Wald, A., Leisenring, W., van Burik, J.A., Bowden, R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175(6): 1459-66.
16. Pappas, P.G., Alexander, B.D., Marr, K. et al. Invasive fungal infections (IFIs) in hematopoi etic stem cell (HSCTs) and organ transplant recipients (OTRs): overview of the TRANSNET database. 42nd Annu Meet Infect Dis Soc Am (Sept 29-Oct 3, Boston) 2004, Abst 671.
17. Baddley, J.W., Stroud, T.P., Salzman, D., Pappas, P.G. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32(9): 1319-24.
18. Pfaller, M.A. and Diekema, D.J. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and aspergillus fumigatus. J Clin Microbiol 2004, 42(10): 4419-31.
19. Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A., Gaynes, R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35(5): 627-30.
20. Wingard, J.R. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol 2007, 20(1): 99-107.
21. Pfaller, M.A., Pappas, P.G., Wingard, J.R. Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 2006, 43(Suppl. 1):S3-14.
22. Caillot, D., Mannone, L., Cuisenier, B., Couaillier, J.F. Role of early dianosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. Clin Microbiol Infect 2001, 7(Suppl. 2): 54-61.
23. Greene, R.E., Schlamm, H.T., Oestmann, J.W. et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007, 44(3): 373-9.
24. Alexander, B.D., Pfaller, M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006, 43(Suppl. 1): S15-27.
25. Marr, K.A., Balajee, S.A., McLaughlin, L., Tabouret, M., Bentsen, C., Walsh, T.J. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J Infect Dis 2004, 190(3): 641-9.
26. Mennink-Kersten, M.A.S.H., Donnelly, J.P., Verweij, P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4(6): 349-57.
27. Marr, K.A., Laverdiere, M., Gugel, A., Leisenring, W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005, 40(12): 1762-9.
28. Marty, F.M., Rubin, R.H. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int 2006, 19(1): 2-11.
29. Maertens, J., Theunissen, K., Verhoef, G. et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005, 41(9): 1242-50.
30. Marr, K.A., Boeckh, M., Carter, R.A., Kim, H.W., Corey, L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39(6): 797-802.
31. Robenshtok, E, Gafter-Gvili, A., Goldberg, E, Weinberger, M, Yeshurun, M., Leibovici, L., Paul, M. Antifungal prophylaxis in cancer patients after chemotherapy or hemtopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007, 25(34): 5471-89.
32. Leather, H.L., Wingard, J.R. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 2006, 20(5): 267-87.
33. Barnes, P., Marr, K. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007, 139(4): 519-31.
34. Pasqualotto, A.C., Nedel, W.L., Machado, T.S., Severo, L.C. Risk factors and outcome for nosocomial breakthrough candidaemia. J Infect 2006, 52(3): 216-22.
35. Tollemar, J., Gross, N., Dolgiras, N., Jarstrand, C., Ringden, O., Hammarstrom, L. Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant 1999, 23(3): 283-90.
36. Package Insert: Nystatin oral suspension. Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY, 2006.
37. Dodds Ashley, E.S., Lewis, R., Lewis, J.S., Martin, C., Andes, D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43(Suppl. 1): S28-39.
38. Gotzsche, P.C., Johansen, H.K. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002, (4): 1-13.
39. Tiphine, M., Letscher-Bru, V., Herbrecht, R. Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999, 1(4): 273-83.
40. Harousseau, J.L., Dekker, A.W., Stamatoullas-Bastard, A. et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000, 44(7): 1887-93.
41. Boogaerts, M., Maertens, J., van Hoof, A. et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001, 48(1): 97-103.
42. Alexander, B.D., Dodds Ashley, E.S., Addison, R.M., Alspaugh, J.A., Chao, N.J., Perfect, J.R. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006, 8(1): 13-20.
43. Pappas, P.G., Rex, J.H., Sobel, J.D., Filler, S.G., Dismukes, W.E., Walsh, T.J., Edwards, J.E. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38(2): 161-89.
44. Stevens, D.A., Kan, V.L., Judson, M.A. et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000, 30(4): 696-709.
45. Perfect, J.R., Klotman, M.E., Gilbert, C.C., Crawford, D.D., Rosner, G.L., Wright, K.A., Peters, W.P. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992, 165(5): 891-7.
46. Tollemar, J., Ringden, O., Andersson, S., Sundberg, B., Ljungman, P., Tyden, G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993, 12(6): 577-82.
47. Kelsey, S.M., Goldman, J.M., McCann, S., Newland, A.C., Scarffe, J.H., Oppenheim, B.A., Mufti, G.J. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999, 23(2): 163-8.
48. Package Insert: Diflucan®. Pfizer Inc., New York, NY, 2004.
49. Goodman, J.L., Winston, D.J., Greenfield, R.A. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326(13): 845-51.
50. Slavin, M.A., Osborne, B., Adams, R. et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study. J Infect Dis 1995, 171(6): 1545-52.
51. Wolff, S.N., Fay, J., Stevens, D. et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000, 25(8): 853-9.
52. Koh, L.P., Kurup, A., Goh, Y.T., Fook-Chong, S.M., Tan, P.H. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002, 71(4): 260-7.
53. Brion, L.P., Uko, S.E., Goldman, D.L. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007, 54(6): 521-9.
54. Package Insert: Sporanox®. Janssen Pharmaceutica Products, L.P., Titusville, NJ, 2006.
55. Oren, I., Rowe, J.M., Sprecher, H. et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006, 38(2): 127-34.
56. Winston, D.J., Maziarz, R.T., Chandrasekar, P.H. et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003, 138(9): 705-13.
57. Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B., Schmidt-Wolf, I.G. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003, 21(24): 4615-26.
58. Marr, K.A., Crippa, F., Leisenring, W. et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103(4): 1527-33.
59. Package Insert: VFEND®. Pfizer Inc., New York, NY, 2006.
60. Kullberg, B.J., Sobel, J.D., Ruhnke, M. et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 2005, 366(9495): 1435-42.
61. Herbrecht, R., Denning, D.W., Patterson, T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347(6): 408-15.
62. Trifilio, S., Pennick, G., Pi, J. et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109(8): 1532-5.
63. Imhof, A., Balajee, S.A., Fredricks, D.N., Englund, J.A., Marr, K.A. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39(5): 743-6.
64. Trifilio, S.M., Bennett, C.L., Yarnold, P.R. et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39(7): 425-9.
65. https://web.emmes.com/study/bmt/protocol/0101_protocol/0101_protocol. html. Accessed 9/1/2007.
66. Wingard, J.R., Carter, S.L., Walsh, T.J. et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. 49th Annu Am Soc Hematol Meet (Dec 8-11, Atlanta) 2007, Abst 163.
67. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™. Prevention and treatment of cancer-related infections. Version 2.2007. Accessed 8/1/2007.
68. Schiller, D.S., Fung, H.B. Posaconazole: An extended-spectrum triazole antifungal agent. Clin Ther 2007, 29(9): 1862-86.
69. Ullmann, A.J., Lipton, J.H., Vesole, D.H. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356(4): 335-47.
70. Package Insert: Noxafil®. Schering Corporation, Kenilworth, NJ, 2006.
71. Package Insert: Mycamine®. Astellas Pharma US, Inc., Deerfield, IL, 2007.
72. Joseph, J.M., Jain, R., Danziger, L.H. Micafungin: A new echinocandin antifungal. Pharmacotherapy 2007, 27(1): 53-67.
73. Cappelletty, D., Eiselstein-McKitrick, K. The echinocandins. Pharmacotherapy 2007, 27(3): 369-88.
74. Package Insert: Cancidas®. Merck and Co., Inc., Whitehouse Station, NJ, 2005.
75. van Burik, J.A., Ratanatharathorn, V., Stepan, D.E. et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10): 1407-16.
76. Chou, L.S., Lewis, R.E., Ippoliti, C., Champlin, R.E., Kontoyiannis, D.P. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007, 27(12): 1644-50.